While management continues to recommend that shareholders approve both Proposals 2 and 3, the company intends to take the actions described below under the following scenarios:
- If both Proposal 2 and 3 are approved - the company will amend its restated certificate of incorporation to authorize an additional 100 million shares of common stock, as described in Proposal 2 but does not intend to also implement a reverse stock split as described in Proposal 3.
- If Proposal 2 is approved and Proposal 3 is not approved - the company will amend its restated certificate of incorporation to authorize an additional 100 million shares of common stock, as described in Proposal 2 and will not implement a reverse stock split as described in Proposal 3.
- If Proposal 3 is approved and Proposal 2 is not approved – as described in the company’s proxy statement, pursuant to its
February 2020securities purchase agreement with certain investors (the “February agreement”), the company will implement a reverse stock split promptly after the meeting and will determine the ratio of the reverse stock split as described in the proxy statement.
- If neither Proposal 2 or 3 is approved – as described in the proxy statement, under the February agreement the company agreed to call additional meetings of stockholders each four months after the initial meeting at which the proposals were considered, to seek stockholder approval of at least one of the proposals until the date that stockholder approval is obtained.
The adjourned meeting will be a completely "virtual" meeting of stockholders, and stockholders will be able to listen and participate in the virtual meeting as well as vote and submit questions during the live webcast of the meeting by visiting www.virtualshareholdermeeting.com/ADMP2020. To participate in the virtual meeting, stockholders will need the control number found on their proxy card or in the instructions that accompanied their proxy materials. Only stockholders of record on the record date of
As described in the proxy statement, a stockholder may use one of the following methods to vote before the
Voting by Telephone, 1-800-690-6903, or Internet, www.proxyvote.com: If you are a holder of record of shares, you can choose to vote by telephone or by Internet. You can vote by telephone by calling the toll-free telephone number on your proxy card, 1-800-690-6903. The website for Internet voting is http://www.proxyvote.com and it is also listed on the proxy card. Please have your proxy card, which includes your stockholder control number, handy when you call or go online. Telephone and Internet voting facilities for stockholders of record will close with respect to the adjourned meeting at
Voting Via the Virtual Annual Meeting Website. To vote during the virtual Meeting, follow the instructions posted at www.virtualshareholdermeeting.com/ADMP2020.
Vote by Mail: Stockholders of record (that is, if you hold your stock in your own name) may sign and date the proxy card you receive and return it in the enclosed stamped, self-addressed envelope.
If your shares are held in the name of a bank, broker, trustee or other nominee holder of record (i.e., in “street name”), you should follow the instructions from the holder of record that you must follow in order for your shares to be voted. The company encourages any stockholder whose shares are held in street name to contact their bank, broker, trustee or other nominee. Telephone and Internet voting generally will be offered to stockholders owning shares through most banks and brokers by following the instruction form provided to you by your broker, bank, trustee, or other nominee.
In connection with the solicitation of proxies, on
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the
Senior Director, Investor Relations
& Corporate Communications
Source: Adamis Pharmaceuticals Corporation